# LuCAB (NCT05340374)

> Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate Cancer

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05340374
- Phase: PHASE1, PHASE2
- Status: ACTIVE_NOT_RECRUITING
- Sponsor: Peter MacCallum Cancer Centre, Australia
- Conditions: Metastatic Castration-resistant Prostate Cancer; mCRPC
- Interventions: Cabazitaxel; 177Lu-PSMA-617
- Enrollment: 35
- Primary outcome: Number of participants with Dose Limiting Toxicities (DLTs)
- Primary outcome: Maximum Tolerated dose (MTD)
- Primary outcome: Recommended Phase 2 Dose (RP2D)

## Preliminary discovery

Commentary in our index that names this trial so far. Final coverage is set when the report is built.

- X threads: 12
- YouTube: 2
- Podcasts: 1

## Order

Standard, $1,250, price fixed at order: https://www.erudio.com/contact?report=lucab-nct05340374

## Free preview

POST https://www.erudio.com/api/trial-requests with {"nct_id": "NCT05340374", "email": "<work email>"}; the inbox owner confirms by the emailed link.